financetom
Business
financetom
/
Business
/
Nexi partners with Amazon Italy to support Bancomat Pay payments
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nexi partners with Amazon Italy to support Bancomat Pay payments
Jul 2, 2024 3:47 AM

MILAN, July 2 (Reuters) - Italian payments group Nexi

said it had signed a partnership with Amazon's ( AMZN )

local arm allowing clients of the e-commerce giant to

shop on its Italian website paying with a local debit card

service dubbed BANCOMAT Pay.

Italy's ATM machine operator BANCOMAT, owned by more than

100 Italian banks, has been working to expand its online payment

service BANCOMAT Pay following an investment by Italian private

euquity fund FSI which is now the biggest single shareholder.

At present, Italians mostly use the 34 million BANCOMAT

cards in circulation for ATM withdrawals.

BANCOMAT is Italy's main debit card payments provider,

managing around 2 billion payment and withdrawal transactions

every year, worth more than 160 billion euros.

Nexi Merchant Solutions Director Italy Filippo Signoretti

said in a statement the company was a good fit for global

players such as Amazon ( AMZN ), when they needed partners with a strong

presence in domestic markets but also international scale.

The payments sector has grown rapidly in recent years,

mostly through a wave of mergers and acquisitions, companies

sought the financial muscle to keep up with technological

advances while contending with the threat from new entrants.

Betting on the prospect of further consolidation, Italian

fund FSI has been investing in the sector by purchasing a 43%

stake in BANCOMAT as well as building a retailers' payment

business in partnership with banks ICCREA and Banco BPM

.

Italy's top bank Intesa Sanpaolo, which owns 18% of

BANCOMAT followed by UniCredit with 11%, acted as a

technology partner in the Nexi-Amazon deal.

Earlier in April, BANCOMAT and Nexi struck a multi-year

contract to develop a centralised technology infrastructure to

allow BANCOMAT to manage on its own new payments it planned to

offer.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With Greenwave Technology
What's Going On With Greenwave Technology
Jun 18, 2024
Greenwave Technology Solutions, Inc. ( GWAV ) shares are trading higher Tuesday after the company announced the completion of its recapitalization. The Details: Greenwave said it has strengthened its balance sheet by approximately $80.5 million since February and has a current cash balance of over $26 million, its strongest cash position in company history.  The company also said it is...
What's Going On With Mustang Bio Stock Tuesday?
What's Going On With Mustang Bio Stock Tuesday?
Jun 18, 2024
Mustang Bio, Inc. ( MBIO ) shares appear to be trending upward Tuesday on continued momentum after the company on Monday announced safety and efficacy data from its Phase 1/2 clinical trial of MB-106, a possible treatment for certain types of blood cancer. 90% of patients treated with MB-106 responded to the treatment with three complete responses. Out of the...
Lexaria Bioscience Hires Contract Research Organization For 12-week Study
Lexaria Bioscience Hires Contract Research Organization For 12-week Study
Jun 18, 2024
11:40 AM EDT, 06/18/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Tuesday that it hired a contract research organization to manage its 12-week chronic study, GLP-1-H24-4, to evaluate different DehydraTECH-GLP-1 formulations and other treatments, focusing on goals such as weight loss and reducing blood sugar levels. Preparations for the study with the CRO have started under an initial...
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment
Jun 18, 2024
11:40 AM EDT, 06/18/2024 (MT Newswires) -- Immunocore Holdings ( IMCR ) said Tuesday it has randomized the first patient in a phase 3 clinical trial of brenetafusp in combination with nivolumab to treat first-line advanced or metastatic cutaneous melanoma, a type of skin cancer. The trial will randomize patients with first-line advanced or metastatic cutaneous melanoma to brenetafusp plus...
Copyright 2023-2025 - www.financetom.com All Rights Reserved